SCHEMBL31401320

SCHEMBL31401320

O=C(O)c1ccc(C2CC2)c(S(=O)(=O)Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
CREBBP Q92793 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
KMO O15229 1/20 0.41
KMT2A Q03164 1/20 0.40
RARG P13631 2/20 0.40
RARB P10826 1/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.39
SLC9A1 P19634 1/20 0.39
SLC6A4 P31645 2/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A3 Q01959 1/20 0.39
TTR P02766 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8895442 0.92 KMO (0.53) CDC25BTDP1CREBBPSMN1; SMN2KMO
SCHEMBL31401408 0.83 SLC9A1 (0.53) CDC25BTDP1CREBBPSMN1; SMN2KMO
SCHEMBL30153250 0.83 ALDH1A1 (0.48) SMN1; SMN2KMT2APKMTSHRSLC6A4
SCHEMBL22636985 0.83 ALDH1A1 (0.48) SMN1; SMN2KMT2APKMTSHRSLC6A4
SCHEMBL31401521 0.80 CREBBP (0.44) CDC25BTDP1CREBBPSMN1; SMN2KMO
SCHEMBL10148390 0.78 RARG (0.56) CREBBPKMORARGRARBTSHR
SCHEMBL23045595 0.77 TRPV4 (0.43) KMT2ATSHR
SCHEMBL665155 0.77 TSHR (0.57) TDP1CREBBPKMORARGRARB
SCHEMBL1424320 0.75 POLB (0.55) CDC25BTDP1SMN1; SMN2KMT2APKM
SCHEMBL18283980 0.75 CA12 (0.55) TDP1CREBBPSMN1; SMN2KMORARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed